ValiRx (LSE:VAL) Gross-Profit-to-Asset %

: 0.00% (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ValiRx's annualized Gross Profit for the quarter that ended in Jun. 2023 was £0.00 Mil. ValiRx's average Total Assets over the quarter that ended in Jun. 2023 was £4.02 Mil. Therefore, ValiRx's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.00%.

ValiRx Gross-Profit-to-Asset % Historical Data

The historical data trend for ValiRx's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Gross-Profit-to-Asset %																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, ValiRx's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, ValiRx's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ValiRx's Gross-Profit-to-Asset % falls into.

ValiRx Gross-Profit-to-Asset % Calculation

ValiRx's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0	/	( (3.524	+	3.976)	/ 2 )
	=	0	/	3.75
	=	0.00 %

ValiRx's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	0	/	( (3.976	+	4.072)	/ 2 )
	=	0	/	4.024
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

ValiRx Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ValiRx's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.